ReviewEcoSal Plus2023
An Overview of Diverse Strategies To Inactivate
Review in EcoSal Plus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Bicyclic δ-Thiolactone Glycomimetics: Stereoselective Synthesis and Discovery of Stereocontrolled Antiphage Activity.The Journal of organic chemistry · 2026Article
- Protecting bacteriophages under UV irradiation with brilliant blue FCF for targeted bacterial control.Biofilm · 2025Article
- Chitosan nano-formulation enhances stability and bactericidal activity of the lytic phage HK6.BMC biotechnology · 2025Article
- Real-time monitoring by interferometric light microscopy of phage suspensions for personalised phage therapy.Scientific reports · 2024Article
- Copper Oxide Electrochemical Deposition to Create Antiviral and Antibacterial Nanocoatings.Langmuir : the ACS journal of surfaces and colloids · 2024Article
- Bacteriophage Challenges in Industrial Processes: A Historical Unveiling and Future Outlook.Pathogens (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bacteriophages are viruses that infect bacteria and thus threaten industrial processes relying on the production executed by bacterial cells. Industries bear huge economic losses due to such recurring and resilient infections. Depending on the specificity of the process, there is a need for appropriate methods of bacteriophage inactivation, with an emphasis on being inexpensive and high efficiency. In this review, we summarize the reports on antiphagents, i.e., antibacteriophage agents on inactivation of bacteriophages. We focused on bacteriophages targeting the representatives of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.